Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07593092 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors | PHASE1 | NOT YET_RECRUITING | 90 | — | — | Jun 1, 2026 | Dec 1, 2028 | May 18, 2026 | 9 | United States |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | PHASE1 | RECRUITING | 282 | — | — | Apr 4, 2024 | Dec 1, 2028 | Mar 17, 2026 | 16 | United States |
| Arm | Type | Description |
|---|---|---|
| Dose Escalation and Dose Expansion of XmAb541 and XmAb808 | EXPERIMENTAL | - |
| Dose escalation and Dose Expansion of XmAb541 | EXPERIMENTAL | Intravenous or Subcutaneous administration |
| Name | Type | Description |
|---|---|---|
| XmAb541 | BIOLOGICAL | Monoclonal Bispecific Antibody |
| XmAb808 | BIOLOGICAL | Monoclonal Bispecific Antibody |
Inclusion Criteria: * Age ≥ 18 years. * CLDN6+ tumor * Histological or cytological documentation of locally advanced, recurrent, or metastatic high grade serous ovarian carcinoma (HGSOC) including fallopian tube or primary peritoneal origin * Adequate Eastern Cooperative Oncology Group performance ...